November 15 - LA Times reporters Scott Glover and Lisa Girion published an investigation that identified 3,733 Southern California deaths, from 2006 to 2011, associated with prescription drugs. In nearly half of these cases, prescription drugs were "the sole cause, or a contributing cause of death."
The investigation, which was published in the LA Times last Sunday, denounced 71 physicians in the Los Angeles, Orange, San Diego and Ventura counties who "prescribed drugs to three or more patients who later fatally overdosed." One doctor profiled in the investigation gave prescriptions to 16 patients who later overdosed. Most of these doctors specialized in pain, psychiatry, and general health.
Last Updated (Monday, 19 November 2012 21:31)
The meningitis outbreak discovered in September has killed nineteen individuals thus far, with four deaths reported in the last 24 hours. The outbreak, which was traced to a steroid contamination, hit Tennessee the hardest, killing eight individuals within the state since the outbreak was reported.
The number of cases of fungal meningitis due to contaminated steroids rose to 245 earlier today. The pharmaceutical corporation responsible for manufacturing these steroids, the New England Compounding Center (NECC), has recalled all of its medications (according to Reuters) and is "warning patients who may have been treated with the drugs to watch for symptoms."
The NECC Framingham facility was raided by special agents of the FDA Tuesday, and a criminal investigation of NECC is rumored to be underway. The FDA has also been placed under closer scrutiny since this outbreak, and the need for tighter governmental regulations against pharmaceutical companies, such as NECC, has been called for.
Last Updated (Thursday, 18 October 2012 22:15)
A California Jury recently awarded $5.5 million in damages to a TransVaginal Mesh patient who suffered urinary incontinence and chronic pain due to the poorly tested medical device. C.R. Bard was found negligent in the handling and marketing of their device, the Avaulta Plus vaginal implant.
This is the first of hundreds of cases against TransVaginal Mesh manufacturers.
Last Updated (Wednesday, 25 July 2012 00:35)
After over 900 people suffered from cardiac arrest at Fresenius Dialysis Clinics, the U.S. Food and Drug Administration ("FDA") issued a Class I recall for GranuFlo and NaturaLyte dialysis concentrates.
A Class I recall places GranuFlo and NaturaLyte in the FDA's most serious medical device recall category. Class I recalls are typically issued in situations where there is a reasonable probability that the use of a product will cause serious adverse health consequences or death.
In conjunction with bicarbonate, GranuFlo and NaturaLyte are administered to dialysis patients in order to neutralize acid that builds up in the blood. Both products reportedly contain much more acetate than other dialysis concentrates, resulting in higher levels of bicarbonate, which is considered to be a significant risk factor for cardiac arrest.
Although Fresenius warned physicians and medical directors at its own dialysis clinics about the issue, Fresenius is being investigated for not issuing the warning to the general public. Specifically, Fresenius issued an internal memo to its own dialysis clinics in November of 2011 regarding the high rate of cardiac arrest that occurred at Fresenius clinics in 2010. According to the memo, 914 hemodialysis patients experienced cardiac arrest at 667 Fresenius facilities in 2010 alone. Fresenius' own study indicated that excess bicarbonate, or alkalosis, significantly increased the risk of heart problems in dialysis patients. However, Fresenius did not notify the public or the FDA about its findings until the FDA received an anonymous copy of the internal memo and commenced its own investigation. Fresenius then issued an Urgent Product Notification warning its customers that GranuFlo and NaturaLyte are associated with elevated bicarbonate levels and an increased risk for cardiac arrest. The FDA issued a Safety Communication in May of 2012, warning about alkali dosing errors for products including GranuFlo and NaturaLyte.
Last Updated (Friday, 29 June 2012 13:59)
Fresenius dialysis products GranuFlo and NaturaLyte were moved this week onto the FDA's list of Class 1 recalls - the most serious recall category, which includes high risk of death or serious side effects. According to the corporation's press release on June 21st, the products had much higher bicarbonate levels than other rival products. These raised levels were associated with many reportedÂ cardiac arrests.
According to the Times, Fresenius was aware of the dangers these products posed in November of 2011. They sent an "internal memo" to their own clinics at that time, but failed to alert the FDA and consumers. The memo stated that, "941 hemodialysis patients had experienced cardiac arrest at 667 Fresenius facilities in 2010."
The failure to properly notify consumers of theseÂ product dangers has led to a federal investigation.
Last Updated (Friday, 29 June 2012 13:33)
Zithromax (Azithromycin), commonly marketed as the "Z-Pack," was the subject of a study published in the New England Journal of Medicine yesterday. The study found "a small increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of azithromycin (Zithromax) compared to persons treated with amoxicillin, ciprofloxacin, or no drug."
Last Updated (Friday, 18 May 2012 07:57)
Pradaxa (Dabigatran) is a blood-thinner medication used to prevent strokes or serious blood clots in people who have atrial fibrillation (a condition in which the heart beats irregularly). According to Boehringer, the maker of Pradaxa, this medication was found to cause internal bleeding in several hundred patients.
Other side effects of Pradaxa range from stomach pain, heart burn, nausea, headache, and joint pain to more serious side effects such as unusual bleeding or bruising, coughing up blood, vomiting bloody materials, bleeding from the gums, frequent nosebleeds, heavy menstrual bleeding, ulcers, and cerebral hemorrhaging.
Last Updated (Tuesday, 24 April 2012 10:16)
The FDA recently announced a label change for the drug Propecia (commonly marketed as Proscar)- a ď»żdrug designed to treat male-pattern hair loss and enlarged prostate glands - to include the warning risk of prostate cancer. Propecia, also known as the 5-alpha reductase inhibitor Finasteride, was found to increase the risk of developing high-grade prostate cancer (the most serious form of prostate cancer) after multiple clinical trials [including The Prostate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE)].
Last Updated (Wednesday, 28 March 2012 11:04)
Tysabri (natalizumab), a drug used to treat multiple sclerosis (MS) or Crohn's disease, was found to increase the risk of developing progressive multifocal leukoencephalopathy (PML) in some patients. PML is "a rare but serious brain infection," according to FDA MedWatch.
Last Updated (Monday, 30 January 2012 14:59)
Multaq (dronedarone) was found to increase the risk of death or serious adverse cardiovascular events if used by patients in permanent atrial fibrillation (AF).Â
On Apr. 27, 2012, the FDA sent warning notices to 10 drug companies manufacturing and distributing dietary supplements that contain dimethylamylamine, also known as DMAA. The FDA cited the companies for marketing the supplements without submitting evidence that the products are safe.
Under law, manufacturers of dietary ingredients are responsible for notifying the FDA within 75 days of marketing their products with evidence that supplements containing new dietary ingredients are safe. "Before marketing products containing DMAA, manufacturers and distributors have a responsibility under the law to provide evidence of the safety of their products. They havenâ€™t done that..." said Daniel Fabricant, PhD, Director of the FDAâ€™s Dietary Supplement Program, in an FDA press release.
Last Updated (Wednesday, 02 May 2012 18:40)
In August of 2011 the FDA announced that the antidepressant Celexa (citalopram hydrobromide) should no longer be used at "doses greater than 40 mg per day because it could cause potentially dangerous abnormalities in the electrical activity of the heart." Celexa is not recommended at any dose for patients with certain conditions because of the risk of QT prolongation. For other patients who require citalopram, the drug label has been modified to include the recommendations that:
Hypnotic Drugs (drugs used to induce sleep such as Zolpidem and Temazepam) are among â€śthe most widely used treatments in adult medicineâ€ť, according to a cohort study published by BMJ. In summary, the study concluded that these sleep-inducing drugs were associated with an increased risk of death, even for patients who were prescribed fewer than 18 doses per year.
According to BMJ, an estimated 6%-10% of American adults used some form of hypnotic drugs in 2010, and an even higher percentage may have used these drugs in parts of Europe. The study revealed that since 1979, sleep-inducing drugs have been found to increase mortality rates. Since then, 24 studies have examined the effects of hypnotic drugs- 18 of which found significant adverse effects.
An ongoing FDA epidemiological study supported the connection between the diabetes drug Actos (used to treat Type II diabetes) and the development of bladder cancer, particularly for patients taking Actos for a year or longer. The FDA warning against Actos came after two European countries banned the drug due to its possible risks.
Written by Drug Recall Writer
Anybody who watches television, surfs the Internet or flips through a magazine is very familiar with advertising for pharmaceutical drugs picturing attractive, healthy and active people. Prescription and over the counter drugs are used by millions of consumers for various ailments, diseases and medical conditions. For most, prescription drugs can provide great benefit or relief. A consequence of the development of many drugs and the marketing to millions of consumers, are serious side effects or other undesired results. In extreme cases, the U.S. Food & Drug Administration (FDA) or manufacturer may recall or withdraw a drug.
Over the past few years, the safety of more than a dozen popular prescription drugs has been examined. In some cases, certain drugs have been recalled following reports of serious injury or death.
The recent recall of numerous popular drugs has resulted in heightened scrutiny of certain blockbuster drugs with hearings before Congress in which at least one FDA researcher suggests that the FDA may be incapable of protecting consumers from unsafe drugs and that several other popular drugs currently on the market may also present unacceptable patient risk. According to a survey by the Department of Health & Human Services Office of Inspector General, about two-thirds of Food & Drug Administration scientists are less than fully confident in the agency's monitoring of the safety of prescription drugs now being sold.
DrugRecalls.com is a consumer resource from product liability lawyers engaged in assisting consumers suffering side effects from pharmaceutical drugs.
Not all drugs referenced on this website have been subject to recall or warning. Patients should never stop taking their medicine without first consulting with their physician.
Written by Drug Recall Lawyer
Lawyer of the Year Award...Through your outstanding leadership and advocacy, you have provided the voice of justice in protecting the basic human rights of your clients."
- California Governor, Gray Davis
"Legal Luminary" - The Wall Street Journal
Drug Recall lawyer Dana Taschner is one of the most respected trial lawyers in the United States. Dana has represented numerous individuals in pharmaceutical cases throughout the United States and founded Drug Recalls to provide helpful news and legal information about significant drug recalls impacting millions of consumers. Dana has provided expert legal analysis on CNN and MSNBC, and has been involved in some of the most significant and challenging legal cases in the United States over the last three decades: See Wall Street Journal article quoting Dana on nationwide consumer lawsuits on July 8, 2011 http://online.wsj.com/article/
"Great Plaintiff Lawyer" - The Huffington Post
Dana has been involved in many of the most significant and serious Food and Drug Administration (FDA) or manufacturer drug recalls in history, including: Silicone Gel Breast Implants (FDA ban in 1992), Norplant (birth control implant recall), Fen-Phen (diet drugs recalled in September 1997), Rezulin (diabetes drug recalled in March 2000), Sulzer (hip device recalled in 2000), Baycol (cholesterol drug recalled in August 2001), Zyprexa (schizophrenia drug warning of 2004), Ortho Evra (birth control patch recalled in 2004) Avandia (diabetes drug recalled in July 2007), Paxil (SSRI Black Box Warning 2004), and Depuy Recall (hip device recalled in August 2010). Dana represented thousands of consumers adversely affected by these products after serious side effects or deaths were reported in connection to these pharmaceuticals. Dana has filed the first legal claim in the Courts of the United States following FDA or manufacturer recall in certain national recall cases.
"The height of professional excellenceâ€¦" - Highest national rating from lawyers and judges for skill and integrity.
For twenty consecutive years Dana has been awarded the highest national AV-rating (preeminent) for his legal ability and ethics based on reviews by judges and lawyers. Dana was awarded the American Bar Association's Sole Practitioner of the Year from a field of 400,000 lawyers, and the United States Senate honored Dana with a Senate Tribute, stating, "Taschner has achieved national recognitionâ€¦ Taschner truly brings honor to his profession." The Senate Majority Leader read into the Congressional Record, "Mr. Taschner's devotion to fighting oppression earned him the American Bar Association's Lawyer of the Year award."